Navigation Links
Report reveals why personalizing support for women with breast cancer could save lives
Date:11/22/2013

SUMMIT, N.J., Nov. 22, 2013 /PRNewswire/ -- Personalizing support for women living with breast cancer could help them achieve better health outcomes through improved adherence, according to a new White Paper published by Atlantis Healthcare.    

(Logo: http://photos.prnewswire.com/prnh/20130627/MM38791)

This latest report from the Adherence Research Summarized™ series has been published to help healthcare providers, organized customers and pharma work with patients to overcome the challenges they face while taking preventative breast cancer therapies.

The issue of non-adherence in breast cancer was recently highlighted by a study from the University of Glasgow showing that improved adherence to Tamoxifen, a breast cancer hormone therapy, could prevent 434 deaths each year among women with breast cancer, and save up to £30 million (equivalent of nearly $50 million) in healthcare costs.[1]

"Research indicates as many as 41% of women choose to discontinue their breast cancer treatment," confirms John Weinman, Professor of Psychology as applied to Medicine at King's College London, who reviewed this new report. "While this may seem surprising, it's important to consider why they make this decision."

"Research shows there are certain factors that contribute to non-adherence in breast cancer, including treatment side effects, an individual's personal beliefs about their treatment and condition, and the quality of their healthcare consultations."

Professor Weinman explains that there are ways to help women overcome these challenges.

"The evidence clearly shows that for a support intervention to improve adherence, it must be personalized. As reasons for non-adherence differ between individuals, interventions should be tailored according to a person's unique needs and preferences."

As described in the report, this approach is currently being investigated by other scientists in breast cancer. In a major project funded by the Breast Cancer Research Foundation, Professor Annette Stanton from the University of California and her colleagues Professor Keith Petrie (University of Auckland) and Dr. Ann Partridge (Harvard Medical School) recruited over 1,000 women who had taken hormone therapy for breast cancer within the previous twelve months.  Their study concluded that different women have different support needs, and these must be addressed to have a significant impact on adherence rates. "Some women may truly benefit from information and education about the importance of medication in terms of survival benefit. Some women may need information on how to deal with the side effects," says Professor Stanton.

Professor Weinman concludes, "Just as treatments for breast cancer are becoming increasingly personalized, so too should interventions designed to support patients taking them."

To download the breast cancer Adherence Research Summarized™ report, click here.

About Atlantis Healthcare
Established in 1993, Atlantis Healthcare creates and executes tailored patient support programs and personalized interventions to address treatment adherence across a wide range of chronic and acute diseases, worldwide.  Led by one of the world's largest health psychology teams, our patient-centric approach is designed to improve health outcomes and deliver optimal value for all healthcare stakeholders. 

Atlantishealthcare.com/US

[1] McCowan C, Wang S, Thompson AM, et al, The value of high adherence to tamoxifen in women with breast cancer: a community-based cohort study, Br J Cancer. 2013 Sep 3;109(5):1172-80. doi: 10.1038/bjc.2013.464. Epub 2013 Aug 15.


'/>"/>
SOURCE Atlantis Healthcare
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
2. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
3. WuXi PharmaTech Files 2011 Annual Report on Form 20-F
4. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
5. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
6. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
7. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
8. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
9. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
10. Chindex International, Inc. to Report First Quarter 2012 Financial Results
11. Pharma IQs Solubility Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... you know that PhRMA member companies invested $65.5 billion in research ... medicines, generics and the supply chain account for 14 percent of ... this (7 percent)? Or that the United States ... in high-growth biopharmaceutical startups? ... The biopharmaceutical industry accounts for ...
(Date:7/17/2017)... , July 17, 2017  MedX Holdings, Inc., ... medical testing, strengthening and rehabilitation equipment, today announced the ... Program. MedX is considered the gold standard for the ... in specialized medical strengthening equipment. ... lease with the physician or practice who prescribe the ...
(Date:7/14/2017)... LAS VEGAS , July 13, 2017 It ... the United States is in the midst of ... Disease Control , since 1999, the number of overdose deaths ... , "resulting in over half a million dead from 2001 ... like codeine, oxycodone, and hydrocodone has similarly quadrupled, drawing a ...
Breaking Medicine Technology:
(Date:7/27/2017)... ... July 27, 2017 , ... MAP Health Management, LLC., ... Fierce Innovation Awards: Healthcare Edition 2017, an awards program from the publisher of ... Health Management/Patient Engagement Solutions. , MAP was selected as a finalist for ...
(Date:7/27/2017)... ... July 27, 2017 , ... Team Novo Nordisk, the world’s first all-diabetes ... pro squad as a stagiaire for the remainder of the 2017 season. One of ... 31st at the Tour of Utah. , “Every season we are excited to move ...
(Date:7/27/2017)... York, NY (PRWEB) , ... July 27, 2017 ... ... to President Barack Obama from 2012-2016, will keynote Day 2 of the HIMSS ... The event kicks off at the Sheraton Boston Hotel, Sept. 11-13, 2017. , ...
(Date:7/26/2017)... , ... July 26, 2017 , ... Capillus, LLC has ... hereditary hair loss. The new Flexible Fitting Design offers a more comfortable, adaptable fit ... is delighted with the improvements to the home-use laser therapy caps intended to improve ...
(Date:7/26/2017)... (PRWEB) , ... July 26, 2017 , ... Six greater Bay Area roller derby leagues ... “Make ‘em Bleed,” the most widely attended series of blood drives in California, beginning July ... blood over the past 4 years -- enough to have helped to save up to ...
Breaking Medicine News(10 mins):